IMUX Overview
Upcoming Projects (IMUX)
-
Reviewing Phase 2 CALLIPER Trial Results of Vidofludimus Calcium in Primary Progressive Multiple Sclerosis from Immunic, Inc.
Ticker: IMUX
Execute By: Dec 31, 2025
Executed Projects (IMUX)
-
A Second Look: Evaluating Immunic's IMU-856 for the Treatment of Celiac Disease with a gastroenterologist.
Ticker: IMUX
Executed On: Jan 17, 2024 at 12:30 PM EST -
Evaluating Immunic's IMU-856 for the Treatment of Celiac Disease
Ticker: IMUX
Executed On: Jan 09, 2024 at 12:00 PM EST -
Investigating the recent interim data from the phase 2 CALLIPER trial of vidofludimus calcium (IMU-838) in patients with progressive multiple sclerosis.
Ticker: IMUX
Executed On: Oct 27, 2023 at 11:30 AM EDT -
A look at IMU-935, a RORγt inverse agonist for the treatment of moderate-severe psoriasis
Ticker: IMUX
Executed On: Mar 14, 2022 at 03:00 PM EDT -
A Second View: Examining IMU-838 (vidofludimus calcium) as a potential therapy for moderate-severe ulcerative colitis ahead of the phase 2 readout of the CALDOSE-1 trial
Ticker: IMUX
Executed On: Feb 28, 2022 at 08:00 AM EST -
A look at IMU-838 (vidofludimus calcium) as a potential therapy for moderate-severe ulcerative colitis ahead of the phase 2 readout of the CALDOSE-1 trial.
Ticker: IMUX
Executed On: Feb 22, 2022 at 09:15 AM EST
Upcoming & Overdue Catalysts (IMUX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (IMUX)
-
Top-line Data Reported from Immunic's (IMUX) Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
Ticker: IMUX
Occurred on: Aug 02, 2020
Strategic Initiatives (IMUX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
